Expand BEAM Menu
BEAM MENU

BEAM Latest Press Releases

-- June 13, 2025 --

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress Globe Newswire 7:00 AM

-- June 3, 2025 --

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease Globe Newswire 7:00 AM

-- May 29, 2025 --

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) Globe Newswire 4:01 PM

-- May 14, 2025 --

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress Globe Newswire 9:30 AM

-- May 13, 2025 --

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference Globe Newswire 7:00 AM

-- May 12, 2025 --

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) Globe Newswire 4:01 PM

-- May 6, 2025 --

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Globe Newswire 7:00 AM

-- April 5, 2025 --

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress Globe Newswire 7:00 AM

-- March 27, 2025 --

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration Globe Newswire 4:01 PM

-- March 10, 2025 --

Beam Therapeutics Announces Pricing of Underwritten Offering Globe Newswire 6:01 AM
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation Globe Newswire 6:00 AM